查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1859021

痤疮药物市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

Acne Medication Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 146 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球痤疮药物市场价值为 111 亿美元，预计到 2034 年将以 5.3% 的复合年增长率增长至 184 亿美元。

痤疮药物市场 - IMG1

痤疮病例的增加，尤其是在15至19岁的青少年群体中，推动了市场扩张，也刺激了对有效痤疮治疗的需求。生活方式的改变、荷尔蒙失衡和环境压力也是加剧痤疮流行、导致口服和外用药物需求增加的因素。此外，皮肤油脂分泌过多和毛囊受刺激引起的白头粉刺激增，也进一步推动了市场成长。痤疮药物属于皮肤科范畴，主要针对寻常性痤疮——一种涉及毛孔堵塞、白头粉刺、黑头粉刺和各种皮损的慢性发炎性疾病。治疗旨在减轻发炎、调节皮脂分泌和抑制细菌生长。随着对不含防腐剂、减少类固醇和清洁标籤配方的需求不断增长，市场也在不断发展，这些配方可以提高患者的依从性并减少副作用。此外，远距医疗和电子商务平台的兴起也提高了寻求痤疮解决方案的患者获得治疗的便利性和参与度。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 111亿美元
预测值 184亿美元
复合年增长率 5.3%

2024年，外用药物占据了73.3%的市场份额，这主要得益于其使用方便且对轻度至中度痤疮的疗效。此类别包括乳膏、乳液、贴片和湿纸巾，可将活性成分直接输送到患处，最大限度地减少全身副作用，同时满足不同肤质的需求。诸如活性成分微囊包裹、泡沫配方和水胶体贴片等创新技术正在提升治疗效果和使用者依从性。皮肤科医生通常将外用药物作为一线治疗方案，它们在多步骤护肤流程中的作用也巩固了其在临床和消费者痤疮治疗中的重要性。

2024年，发炎性痤疮市场规模预计将达到87亿美元，这主要得益于此类痤疮的严重性以及对标靶治疗的需求。该市场涵盖丘疹、脓疱、结节和囊肿等症状，通常需要局部和全身治疗相结合。治疗重点在于缓解中重度痤疮相关的发炎、红肿和细菌感染。人们对早期介入以预防疤痕形成的认识不断提高，也加速了处方药在发炎性痤疮治疗中的应用。

2024年，北美痤疮药物市占率达到39.7%。该地区的成长主要源于寻常性痤疮的高发病率，以及完善的医疗基础设施和人们对有效痤疮治疗意识的不断提高。美国、加拿大和墨西哥等国家是推动区域需求的主要力量，受益于个人化皮肤病学等技术的进步，该技术结合了基因组分析，可实现更精准的治疗。公共卫生宣传活动以及处方药和非处方药消费量的成长进一步促进了市场扩张。

全球痤疮药物市场的主要参与者包括拜耳、施泰福（葛兰素史克）、鲁宾製药、梯瓦製药、博士伦、帕拉泰克製药、高德美、瑞迪博士实验室、阿科恩、太阳製药、艾尔建（艾伯维）、梅恩製药、艾尔米拉尔、利洁时和托伦特製药。为了巩固市场地位，痤疮药物市场的企业专注于创新，开发先进配方，例如不含防腐剂和减少类固醇的产品，以改善患者疗效并减少副作用。他们也正在拓展产品组合，涵盖针对不同类型痤疮的口服和外用疗法。与医疗保健提供者建立策略合作伙伴关係，并投资于远距医疗和电子商务等数位平台，有助于提高产品的可及性和患者参与度。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

  • 产业生态系分析
    • 供应商格局
    • 每个阶段的价值增加
    • 影响价值链的因素
  • 产业影响因素
    • 成长驱动因素
      • 寻常性痤疮盛行率不断上升
      • 生活方式和环境诱因
      • 皮肤科製剂的进展
      • 人们对医疗保健的认识和获取途径不断提高
    • 产业陷阱与挑战
      • 治疗相关副作用和抗药性
      • 服务不足地区的接入有限
    • 市场机会
      • 基于微生物组和荷尔蒙标靶疗法的创新
      • 人工智慧驱动的护肤和个人化护理方案的拓展
  • 成长潜力分析
  • 监管环境
  • 未来市场趋势
  • 技术格局
    • 目前技术
    • 新兴技术
  • 专利分析
  • 报销方案
  • 管道分析
  • 定价分析
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係与合作
    • 新产品发布
    • 扩张计划

第五章：市场估算与预测：依产品划分，2021-2034年

  • 主要趋势
  • 维他命A酸
  • 抗生素
  • 水杨酸
  • 过氧化芐
  • 壬二酸
  • 其他产品

第六章：市场估价与预测：依配方划分，2021-2034年

  • 主要趋势
  • 主题
    • 乳霜和乳液
    • 补丁和擦拭垫
  • 口服
    • 片剂和胶囊
    • 粉末
    • 液体

第七章：市场估算与预测：依痤疮类型划分，2021-2034年

  • 主要趋势
  • 发炎性痤疮
  • 非发炎性痤疮

第八章：市场估算与预测：依类型划分，2021-2034年

  • 主要趋势
  • 处方药
  • 非处方药

第九章：市场估计与预测：依年龄组别划分，2021-2034年

  • 主要趋势
  • 12至18
  • 19至35岁
  • 35岁以上

第十章：市场估价与预测：依配销通路，2021-2034年

  • 主要趋势
  • 离线频道
    • 零售商店
    • 药房和药品商店
    • 皮肤科诊所/医院
  • 线上管道

第十一章：市场估计与预测：按地区划分，2021-2034年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十二章：公司简介

  • Akorn
  • Allergan (AbbVie)
  • Almirall SA
  • Bausch Health
  • Bayer
  • Dr. Reddy's Laboratories
  • Galderma
  • Lupin Pharmaceuticals
  • Mayne Pharmaceuticals
  • Paratek Pharmaceuticals
  • Reckitt Benckiser
  • Stiefel (GSK)
  • Sun Pharmaceutical
  • Teva Pharmaceuticals
  • Torrent Pharmaceuticals
  • Viatris
简介目录
Product Code: 3010

The Global Acne Medication Market was valued at USD 11.1 billion in 2024 and is estimated to grow at a CAGR of 5.3% to reach USD 18.4 billion by 2034.

Acne Medication Market - IMG1

The expansion is driven by increasing acne cases, particularly among teenagers aged 15 to 19, which fuels the demand for effective acne treatments. Lifestyle changes, hormonal imbalances, and environmental stressors are also contributing factors that intensify acne prevalence, leading to a higher need for both oral and topical medications. Additionally, the surge in whiteheads caused by oily skin and irritated hair follicles is pushing market growth further. The acne medication segment falls within dermatology, focusing on managing acne vulgaris a chronic inflammatory condition involving clogged pores, whiteheads, blackheads, and various lesions. Treatments aim to reduce inflammation, regulate sebum production, and inhibit bacterial growth. The market is also evolving with the rising demand for preservative-free, steroid-sparing, and clean-label formulations that enhance patient compliance and reduce side effects. Furthermore, the rise of telehealth and e-commerce platforms is improving accessibility and engagement for patients seeking acne solutions.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$11.1 Billion
Forecast Value$18.4 Billion
CAGR5.3%

In 2024, the topical medication segment held 73.3% share, owing to its ease of application and effectiveness in treating mild to moderate acne. This category includes creams, lotions, patches, and wipes that deliver active ingredients directly to the affected skin, minimizing systemic side effects while catering to diverse skin types. Innovations such as encapsulated actives, foam formulations, and hydrocolloid patches are boosting treatment effectiveness and user adherence. Dermatologists commonly prescribe topical treatments as first-line therapy, and their role in multi-step skincare routines has cemented their importance in both clinical and consumer acne care.

The inflammatory acne segment generated USD 8.7 billion in 2024, driven by the severity of this acne type and the need for targeted treatment. This segment covers conditions like papules, pustules, nodules, and cysts, which often require a combination of topical and systemic therapies. Treatments focus on alleviating inflammation, redness, swelling, and bacterial infection associated with moderate to severe acne. Growing awareness about early intervention to prevent scarring has also accelerated the use of prescription medications in managing inflammatory acne.

North America Acne Medication Market held a 39.7% share in 2024. The region's growth stems from the high prevalence of acne vulgaris, supported by strong healthcare infrastructure and rising awareness about effective acne management. Countries including the United States, Canada, and Mexico drive regional demand, benefiting from advancements like personalized dermatology, which incorporates genomic profiling for more precise treatments. Public health campaigns and increasing consumption of both prescription and over-the-counter products further bolster market expansion.

Leading players in the Global Acne Medication Market include Bayer, Stiefel (GSK), Lupin Pharmaceuticals, Teva Pharmaceuticals, Bausch Health, Paratek Pharmaceuticals, Galderma, Dr. Reddy's Laboratories, Akorn, Sun Pharmaceutical, Allergan (AbbVie), Mayne Pharmaceuticals, Almirall, Reckitt Benckiser, and Torrent Pharmaceuticals. To strengthen their position, companies in the Acne Medication Market focus on innovation through the development of advanced formulations like preservative-free and steroid-sparing products, which improve patient outcomes and reduce side effects. They are also expanding their portfolios to include oral and topical therapies targeting diverse acne types. Strategic partnerships with healthcare providers and investment in digital platforms such as telehealth and e-commerce enhance product accessibility and patient engagement.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumption and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Formulation trends
    • 2.2.4 Acne type trends
    • 2.2.5 Type trends
    • 2.2.6 Age group trends
    • 2.2.7 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of acne vulgaris
      • 3.2.1.2 Lifestyle and environmental triggers
      • 3.2.1.3 Advancements in dermatological formulations
      • 3.2.1.4 Growing awareness and access to care
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Treatment-related side effects and resistance
      • 3.2.2.2 Limited access in underserved regions
    • 3.2.3 Market opportunities
      • 3.2.3.1 Innovation in microbiome-based and hormone-targeted therapies
      • 3.2.3.2 Expansion of AI-driven skincare and personalized regimens
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Future market trends
  • 3.6 Technological landscape
    • 3.6.1 Current technologies
    • 3.6.2 Emerging technologies
  • 3.7 Patent analysis
  • 3.8 Reimbursement scenario
  • 3.9 Pipeline analysis
  • 3.10 Pricing analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Retinoids
  • 5.3 Antibiotics
  • 5.4 Salicylic acid
  • 5.5 Benzyl peroxide
  • 5.6 Azelaic acid
  • 5.7 Other products

Chapter 6 Market Estimates and Forecast, By Formulation, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Topical
    • 6.2.1 Creams and lotions
    • 6.2.2 Patches and wiping pads
  • 6.3 Oral
    • 6.3.1 Tablets and capsules
    • 6.3.2 Powders
    • 6.3.3 Liquids

Chapter 7 Market Estimates and Forecast, By Acne Type, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Inflammatory acne
  • 7.3 Non-inflammatory acne

Chapter 8 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Prescription drugs
  • 8.3 Over the counter drugs

Chapter 9 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 12 to 18
  • 9.3 19 to 35
  • 9.4 Above 35

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 Offline channels
    • 10.2.1 Retail stores
    • 10.2.2 Pharmacies and drug stores
    • 10.2.3 Dermatology clinics/hospitals
  • 10.3 Online channels

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Netherlands
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 South Korea
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Argentina
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 UAE

Chapter 12 Company Profiles

  • 12.1 Akorn
  • 12.2 Allergan (AbbVie)
  • 12.3 Almirall S.A.
  • 12.4 Bausch Health
  • 12.5 Bayer
  • 12.6 Dr. Reddy’s Laboratories
  • 12.7 Galderma
  • 12.8 Lupin Pharmaceuticals
  • 12.9 Mayne Pharmaceuticals
  • 12.10 Paratek Pharmaceuticals
  • 12.11 Reckitt Benckiser
  • 12.12 Stiefel (GSK)
  • 12.13 Sun Pharmaceutical
  • 12.14 Teva Pharmaceuticals
  • 12.15 Torrent Pharmaceuticals
  • 12.16 Viatris